Paratek To Acquire Optinose, Expanding Portfolio Beyond Antibiotics
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.